Trial Profile
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of AZD8186 in Patients With Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient/Mutated or PIK3CB Mutated/ Amplified Advanced Solid Malignancies as Monotherapy and in Combination With Abiraterone Acetate or AZD2014
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Mar 2022
Price :
$35
*
At a glance
- Drugs AZD-8186 (Primary) ; Vistusertib (Primary) ; Abiraterone acetate; Prednisone
- Indications Advanced breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 04 Mar 2022 Interim results (n=161) assessing the safety and tolerability of the selective PI3KB inhibitor AZD8186, identify a recommended phase II dose, and assess preliminary efficacy in combination with abiraterone acetate or vistusertib, published in the Clinical Cancer Research.
- 28 May 2020 Status changed from active, no longer recruiting to completed.
- 26 Sep 2019 Planned End Date changed from 30 Sep 2019 to 31 Jan 2020.